Nuo Therapeutics, Inc. (AURX)
| Market Cap | 47.92M -27.3% |
| Revenue (ttm) | 4.13M +155.8% |
| Net Income | -2.38M |
| EPS | -0.05 |
| Shares Out | 48.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 1.0000 |
| Previous Close | 1.1070 |
| Day's Range | 0.9900 - 1.0000 |
| 52-Week Range | 0.9359 - 3.2300 |
| Beta | -831.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Nuo Therapeutics
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix,... [Read more]
Financial Performance
In 2025, Nuo Therapeutics's revenue was $3.31 million, an increase of 142.72% compared to the previous year's $1.37 million. Losses were -$2.51 million, 8.11% more than in 2024.
Financial StatementsNews
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic...
Nuo Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Kyle Bauser initiated coverage of Nuo Therapeutics (AURX) with a Buy rating and $3 price target The firm sees the company’s technology as positioned for “significant growth”…
Nuo Therapeutics management to meet virtually with Roth Capital
Virtual Meeting to be held on December 4 hosted by Roth Capital.
Nuo Therapeutics files $14M common stock offering
16:49 EDT Nuo Therapeutics (AURX) files $14M common stock offering
Nuo Therapeutics enters Centrio distribution pact with Smith & Nephew
Nuo Therapeutics (AURX) announced it has entered into an exclusive private label distribution agreement with Smith & Nephew (SNN). Under the agreement, Smith+Nephew will market and sell Centrio Platel...
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging...
Nuo Therapeutics, PAM Health partner to advance access to wound healing therapy
A multi-year exclusive agreement between PAM Health and Nuo Therapeutics (AURX) means Nuo’s Aurix System will serve as the sole platelet-rich plasma wound care therapy across all of PAM Health’s…
Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chro...
Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...
Nuo Therapeutics’ Aurix System added to WCA formulary
Nuo Therapeutics announces that Wound Care Advantage, WCA, the nation’s leading wound care consulting firm has added the Aurix System to its formulary. Wound Care Advantage has established a large…
Nuo Therapeutics' Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...
Nuo Therapeutics Provides Corporate and Business Update
Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase